Clinical Trial Update: A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy [Phase 2]

View source ↗

Summary

A Phase II study evaluating continuous hepatic arterial infusion with floxuridine and dexamethasone in patients with unresectable primary hepatic malignancy has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Cancer

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Floxuridine (floxuridine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hepatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-08-04